Mucosal innate immune factors in secretions from high-risk individuals immunized with a bivalent gp120 vaccine.

James E Cummins, Maxine Denniston, Kenneth H Mayer, Robert Pickard, Richard M Novak, Parrie Graham, Marc Gurwith, Karen Orelind, Marta L Ackers, Charlene S Dezzutti

Journal: AIDS research and human retroviruses 2007;23(5):748-54

PMID: 17531002

Full Text on Atypon View on PubMed

Abstract

This study examined the effect of an HIV vaccine on mucosal innate factor expression. Serum, gingival fluid, and genital mucosal secretions were collected from high-risk women and men enrolled in an HIV-1 efficacy vaccine trial and from low-risk women and men. Samples were tested by standard ELISA for lactoferrin, myeloid-related protein-8/14, and secretory leukocyte protease inhibitor. No consistent significant changes in innate factor levels were found in serum or secretions from vaccinees compared to placebo recipients or from high-risk compared to low-risk individuals. Because of the importance of innate immunity in host defense, evaluation of the mucosal innate immune system should be included in future HIV prevention trials.

Address: Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. [email protected]

DOI: 10.1089/aid.2006.0233

Link outs

Free resources

Medical:

https://medlineplus.gov/hivinwomen.html

Subscription / membership required

Full Text Sources:

https://www.liebertpub.com/doi/10.1089/aid.2006.02...

MeSH Terms: AIDS Vaccines, Adolescent, Adult, Bodily Secretions, Calgranulin B, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, HIV Envelope Protein gp120, HIV Infections, HIV-1, Humans, Immunity, Innate, Immunity, Mucosal, Lactoferrin, Male, Middle Aged, Risk Factors, Secretory Leukocyte Peptidase Inhibitor, Vaccines, Synthetic